Please login to the form below

Not currently logged in
Email:
Password:

Sanofi poaches Peugeot's finance head

Jean-Baptiste Chasseloup de Chatillon joins the French drugmaker as chief financial officer

Sanofi

Sanofi has appointed car maker Peugeot's finance director Jean-Baptiste Chasseloup de Chatillon to take over as its new chief financial officer.

Chasseloup de Chatillon will join the French drug maker as its executive vice president and chief financial officer from 1 October, when he will succeed Jérome Contamine, who is set to retire at the end of September.

Chasseloup de Chatillon most recently served in a similar position for PSA Group, a French car manufacturer comprising of the Peugeot, Citroen and Vauxhall brands to name a few.

Jean-Baptiste

There, he played a crucial part in reviving the business after a very close call with bankruptcy back in 2012.

Sanofi’s chief executive Olivier Brandicourt says Chasseloup de Chatillon will be of “great value” to the company after his involvement in the “impressive” turnaround of PSA Group.

It seems that Sanofi, which is currently restructuring the business by trimming costs, is also targeting financial prosperity with this hire, following its unstable start to 2018.

The group saw sales from its diabetes blockbuster Lantus (insulin glargine) plummet 18% to €911m (1.1bn) in the first quarter, quite a difference from the drug’s peak in 2014, when it reached a high of $8.5bn.

However it has made some promising new acquisitions this year, including haemophilia and blood disorder specialists Bioverativ, which it bought for $11.6bn.

It also made a play for nanobody focused biopharma Ablynx, which it acquired for €3.9bn, along with its lead candidate and orphan drug caplacizumab for rare blood disorder acquired thrombotic thrombocytopenic purpura (aTTP).

On top of this, Sanofi is also re-shaping its pipeline after it made a deal to transfer its anti-invectives unit to biotech Evotec.

The French pharma giant will be highlighting its future plans and ongoing business transformation at its second quarter results on 31 July.

Article by
Gemma Jones

19th June 2018

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....